NF-κB in biology and targeted therapy: new insights and translational implications
Q Guo, Y Jin, X Chen, X Ye, X Shen, M Lin… - … and Targeted Therapy, 2024 - nature.com
NF-κB signaling has been discovered for nearly 40 years. Initially, NF-κB signaling was
identified as a pivotal pathway in mediating inflammatory responses. However, with …
identified as a pivotal pathway in mediating inflammatory responses. However, with …
A review of the application of inflammatory biomarkers in epidemiologic cancer research
Inflammation is a facilitating process for multiple cancer types. It is believed to affect cancer
development and progression through several etiologic pathways, including increased …
development and progression through several etiologic pathways, including increased …
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma …
YH Messinger, PS Gaynon, R Sposto… - Blood, The Journal …, 2012 - ashpublications.org
Therapy of relapsed pediatric acute lymphoblastic leukemia (ALL) is hampered by low
remission rates and high toxicity, especially in second and subsequent relapses. Our phase …
remission rates and high toxicity, especially in second and subsequent relapses. Our phase …
Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
The biologic and clinical significance of KIT overexpression that associates with KIT gain-of-
function mutations occurring in subsets of acute myeloid leukemia (AML)(ie, core binding …
function mutations occurring in subsets of acute myeloid leukemia (AML)(ie, core binding …
[HTML][HTML] AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review
G Bianchi, Y Zhang, RL Comenzo - JACC: CardioOncology, 2021 - Elsevier
Immunoglobulin light chain (AL) amyloidosis is an incurable plasma cell disorder
characterized by deposition of fibrils of misfolded immunoglobulin free light chains (FLC) in …
characterized by deposition of fibrils of misfolded immunoglobulin free light chains (FLC) in …
Heparanase: From basic research to therapeutic applications in cancer and inflammation
I Vlodavsky, P Singh, I Boyango, L Gutter-Kapon… - Drug resistance …, 2016 - Elsevier
Heparanase, the sole heparan sulfate degrading endoglycosidase, regulates multiple
biological activities that enhance tumor growth, angiogenesis and metastasis. Heparanase …
biological activities that enhance tumor growth, angiogenesis and metastasis. Heparanase …
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
Under physiological and pathological conditions, cells activate the unfolded protein
response (UPR) to deal with the accumulation of unfolded or misfolded proteins in the …
response (UPR) to deal with the accumulation of unfolded or misfolded proteins in the …
Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management
Abstract Purpose of Review Multiple myeloma is the second most common hematologic
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …
malignancy in the USA, with over 32,000 new cases and nearly 13,000 deaths expected in …
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N Amodio, MT Di Martino, U Foresta, E Leone… - Cell death & …, 2012 - nature.com
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications
in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways …
in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways …
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
JW Friedberg, JM Vose, JL Kelly… - Blood, The Journal …, 2011 - ashpublications.org
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in
patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory …
patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory …